Dr. Jason Mouabbi, Dr. Fenting Yan, & Dr. Paolo Tarantino - First-Line T-DXd in HER2+ mBC

Dr. Rena Callahan & Dr. Aditya Bardia - Integrating T-DXd in HER2+ Breast Cancer: DB11, DB05 & DB09

HER2-positive breast cancer treatment is evolving rapidly. With FDA approvals from DESTINY-Breast11 and DESTINY-Breast05, when should clinicians incorporate trastuzumab deruxtecan (T-DXd) into practice—and how should it be used across early-stage and into metastatic disease?In this in-depth discussion, Dr. Rena Callahan and Dr. Aditya Bardia explore how these landmark studies are changing treatment decisions today across neoadjuvant, adjuvant, and metastatic settings—including the management of residual disease and the optimization of first-line metastatic care.Key topics discussed:• How DESTINY-Breast11 is changing neoadjuvant treatment strategies• DESTINY-Breast05 and the role of T-DXd for residual disease• Which patients should receive T-DXd versus T-DM1• Managing ILD risk and monitoring requirements• Treatment decisions for patients who do not achieve pCR• Rechallenging T-DXd after recurrence• First-line metastatic HER2-positive breast cancer after DESTINY-Breast09• Deep responses, complete responses, and long-term outcomes• T-DXd versus THP in clinical practice• PATINA, HER2CLIMB-05, and evolving maintenance strategies• CNS metastases and the role of HER2-targeted ADCs• Treatment holidays, ctDNA monitoring, and personalized careAs T-DXd moves into earlier lines of therapy, oncologists are facing new questions around sequencing, toxicity management, and optimizing long-term outcomes. This conversation provides practical insights for both academic and community clinicians navigating this rapidly changing landscape.Subscribe for more expert oncology discussions, breast cancer updates, and clinical trial insights from Community Health Media.

Dr. Neil Iyengar, Dr. Joyce O'Shaughnessy, & Dr. Ana Garrido-Castro - Evolving ADCs in 1L mTNBC

The first-line treatment landscape for metastatic triple-negative breast cancer is changing rapidly.Dr. Neil Iyengar, Dr. Joyce O'Shaughnessy, and Dr. Ana Garrido-Castro discuss how ADCs are reshaping frontline TNBC care and what the latest clinical evidence means for real-world practice.The conversation explores:• The evolution of metastatic TNBC treatment• Why many patients never reach second-line therapy• The impact of ASCENT and sacituzumab govitecan• ASCENT-03 and ASCENT-04 trial results• TROPION-Breast02 and datopotamab deruxtecan• The role of crossover in interpreting overall survival• PFS, OS, and PFS2 as clinical trial endpoints• Selecting between SG and Dato-DXd• Managing neutropenia, stomatitis, ocular toxicity, and ILD• Shared decision-making in frontline TNBC• Why using the best therapy first may matter mostThis comprehensive discussion examines the evidence driving ADC use in metastatic TNBC and how clinicians can individualize treatment selection in an increasingly complex therapeutic landscape.Watch now to hear how ADCs are reshaping frontline TNBC care.

MATTERHORN Roundtable: Perioperative FLOT & Immunotherapy Updates in Gastric Cancer

The treatment landscape for perioperative gastric cancer is changing rapidly.In this expert roundtable, leading GI oncology specialists discuss the practice-changing impact of the MATTERHORN trial, the role of immunotherapy in resectable gastric cancer, and how emerging data from ASCO 2026 is influencing treatment decisions in both academic and community settings.Featuring insights from Dr. Zev Wainberg, Dr. Nataliya Uboha, Dr. Sunnie Kim, Dr. Harry Menon, Dr. Angela Alistar, Dr. Raji Shameem, and Dr. Timothy Brown.Key topics discussed:• MATTERHORN trial results and clinical implications• Adding durvalumab to perioperative FLOT chemotherapy• Event-free survival and overall survival outcomes• Pathologic complete response (pCR) and major pathologic response (MPR)• The role of PD-L1 testing and biomarker selection• Interpreting subgroup analyses in gastric cancer• FLOT as the current perioperative standard of care• Immunotherapy in resectable gastric and gastroesophageal cancers• Global perspectives on gastric cancer treatment• Practical considerations for community oncologists• Future directions in perioperative upper GI cancer researchAs immunotherapy moves earlier into the treatment journey, clinicians are faced with new opportunities—and new questions—about patient selection, biomarkers, treatment sequencing, and long-term outcomes.Subscribe for more expert oncology discussions, clinical trial updates, and insights from leading cancer specialists.

EMERALD-3 Roundtable: Hepatocellular Carcinoma Trial Breakdown & Insights

Could EMERALD-3 redefine the treatment paradigm for unresectable hepatocellular carcinoma?In this special roundtable discussion recorded at ASCO 2026, Dr. Ghassan Abou-Alfa is joined by Dr. Gentry King, Dr. Mehmet Akce, Dr. Pierre Gholam, Dr. Lingling Du, Dr. Adam Burgoyne, Dr. Lipika Goyal, and Dr. Riad Salem to break down the landmark EMERALD-3 study.The panel explores the scientific rationale for combining transarterial chemoembolization (TACE) with immunotherapy and antiangiogenic therapy, while reviewing key efficacy findings from the EMERALD-3 study. Beyond the data, the experts discuss how locoregional therapies can enhance immune responses, and examine the practical challenges of patient selection, multidisciplinary decision-making, treatment sequencing, and the evolving role of interventional radiology in modern HCC management.Topics discussed include:• EMERALD-3 trial design and results• TACE plus systemic therapy in HCC• Durvalumab and immunotherapy strategies• Lenvatinib and antiangiogenic therapy• Synergy between embolization and immunotherapy• Locoregional therapy in unresectable HCC• Progression-free survival and clinical outcomes• Multidisciplinary management of liver cancer• Interventional radiology and oncology collaboration• Patient selection for combination therapy• Future directions in hepatocellular carcinoma treatment• How EMERALD-3 may influence clinical practiceAs treatment options continue to expand, understanding how systemic therapy and locoregional interventions work together may be key to improving outcomes for patients with liver cancer.Subscribe for more expert oncology discussions, clinical trial updates, and insights from leading cancer specialists.

Dr. Ursa Brown Glaberman & Dr. Karthik Giridhar- Managing Capiva-sertib & the AKT Path-way in 2L mBC

How are we navigating the evolving landscape of second-line treatment for metastatic HR-positive, HER2-negative breast cancer?In this full-length discussion, Dr. Ursa Brown-Glaberman and Dr. Karthik Giridhar explore one of the most rapidly evolving areas in breast oncology: treatment selection after progression on first-line endocrine therapy and CDK4/6 inhibitors.The conversation examines how molecular profiling, ctDNA testing, AKT pathway targeting,PIK3CA alterations, ESR1 mutations, and emerging biomarkers are reshaping decision-making in the second-line setting. The experts also discuss how they approach endocrine therapy sequencing, when to transition to ADCs, and how toxicity, quality of life, and patient preferences influence treatment selection.Topics discussed include:• Second-line treatment strategies in HR-positive metastatic breast cancer• Endocrine therapy sequencing after CDK4/6 inhibitors• ESR1 mutation testing and ctDNA monitoring• Tissue biopsy versus liquid biopsy• PIK3CA mutations and targeted therapies• Capivasertib versus alpelisib decision-making• AKT pathway inhibition in metastatic disease• Germline BRCA and PALB2 testing• Biomarker-driven treatment selection• When to transition from endocrine therapy to ADCs• Quality of life considerations in metastatic breast cancer• The future of personalized treatment sequencingAs the treatment landscape continues to expand, understanding how to personalize second-line therapy has become one of the most important challenges in modern breast cancer care.Subscribe for more expert oncology discussions, breast cancer treatment updates, and clinical insights from leading specialists.